Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structural Effects of Two Camelid Nanobodies Directed to Distinct C-Terminal Epitopes on α-Synuclein

20 Apr 2016

Abstract excerpt

α-Synuclein is an intrinsically disordered protein whose aggregation is associated with Parkinson's disease and other related neurodegenerative disorders. Recently, two single-domain camelid antibodies (nanobodies) were shown to bind α-synuclein with high affinity. Herein, we investigated how these two nanobodies (NbSyn2 and NbSyn87), which are directed to two distinct epitopes within the C-terminal domain of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular transport and secretion
Share to Neurological disorders and treatments
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27096466
DOI: 10.1021/acs.biochem.6b00149

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structural Effects of Two Camelid Nanobodies Directed to Distinct C-Terminal Epitopes on α-SynucleinPMID 27096466Read ↗

Novel engineered nanobodies specific for N‐terminal region of alpha‐synuclein recognize Lewy‐body pathology and inhibit <i>in‐vitro</i> seeded aggregation and toxicitySemantic proximity Read ↗

Disulfide engineering reveals unexpected pro- and anti-aggregation conformers of human α-synucleinSemantic proximity Read ↗

A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme.Semantic proximity Read ↗

Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic beta2-microglobulin variant.Semantic proximity Read ↗

A nanobody binding to non-amyloidogenic regions of the protein human lysozyme enhances partial unfolding but inhibits amyloid fibril formation.Semantic proximity Read ↗

Conformational equilibria in monomeric alpha-synuclein at the single-molecule level.Semantic proximity Read ↗

Nanobodies as Novel Tools to Modulate Human Frataxin Stability and FunctionSemantic proximity Read ↗

Effect of Humanizing Mutations on the Stability of the Llama Single-Domain Variable Region.Semantic proximity Read ↗

Inhibiting Aggregation of α-Synuclein with Human Single Chain Antibody FragmentsSemantic proximity Read ↗

Rational design of antibodies targeting specific epitopes within intrinsically disordered proteinsSemantic proximity Read ↗

A relationship between the aggregation rates of α-synuclein variants and the β-sheet populations in their monomeric forms.Semantic proximity Read ↗

Engineering a Camelid Antibody Fragment That Binds to the Active Site of Human Lysozyme and Inhibits Its Conversion into Amyloid FibrilsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.